wzb117 has been researched along with Adenocarcinoma-of-Lung* in 1 studies
1 other study(ies) available for wzb117 and Adenocarcinoma-of-Lung
| Article | Year |
|---|---|
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Adenocarcinoma (ADC) and squamous cell carcinoma (SqCC) are the two predominant subtypes of non-small cell lung cancer (NSCLC) and are distinct in their histological, molecular and clinical presentation. However, metabolic signatures specific to individual NSCLC subtypes remain unknown. Here, we perform an integrative analysis of human NSCLC tumour samples, patient-derived xenografts, murine model of NSCLC, NSCLC cell lines and The Cancer Genome Atlas (TCGA) and reveal a markedly elevated expression of the GLUT1 glucose transporter in lung SqCC, which augments glucose uptake and glycolytic flux. We show that a critical reliance on glycolysis renders lung SqCC vulnerable to glycolytic inhibition, while lung ADC exhibits significant glucose independence. Clinically, elevated GLUT1-mediated glycolysis in lung SqCC strongly correlates with high Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cohort Studies; Deoxyglucose; Female; Fluorodeoxyglucose F18; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucose; Glucose Transporter Type 1; Glycolysis; Humans; Hydroxybenzoates; Lung; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Phenotype; Positron-Emission Tomography; Prognosis; Survival Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |